Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Igor Puzanov, Mohammed Milhem, David R. Minor, +9

Journal of Clinical Oncology

Activation of m-Calpain (Calpain II) by Epidermal Growth Factor Is Limited by Protein Kinase A Phosphorylation of m-Calpain

Hidenori Shiraha, Angela Glading, Jeffrey Chou, +2

Molecular and Cellular Biology

Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide

Christopher G. Kanakry, David G. Coffey, Andrea Towlerton, +9

JCI Insight

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

Georgina V. Long, Reinhard Dummer, Antoni Ribas, +17

Journal of Clinical Oncology

ImmunologyImmune RegulationImmunoeditingImmunotherapeuticsDermatology +20

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

Igor Puzanov, Mohammed Milhem, Robert Hans Ingemar Andtbacka, +9

Journal of Clinical Oncology

Ipi TxImmunologyImmunoeditingImmunotherapeuticsDermatology +20

Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors

Melissa L. Johnson, Fadi Braiteh, Juneko E. Grilley‐Olson, +7

JAMA Oncology

Tracking the fate and origin of clinically relevant adoptively transferred CD8 ⁺ T cells in vivo

Aude G. Chapuis, Cindy Desmarais, Ryan Emerson, +11

Science Immunology

Distribution of gelsolin and phosphoinositol 4,5-bisphosphate in lamellipodia during EGF-induced motility

Jeffrey Chou, Donna B. Stolz, Nancy A. Burke, +2

The International Journal of Biochemistry & Cell Biology

MechanobiologyCell PhysiologyEgf-induced MotilityPhysiologyCytoskeleton +8

NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine

Seth M. Pollack, Yonqing Li, Megan J. Blaisdell, +9

PLoS ONE

<i>C19orf48</i> Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients

Scott S. Tykodi, Nobuharu Fujii, Nathalie Vigneron, +11

Clinical Cancer Research